Form 4 for NEO NEOGENOMICS INC
Accepted 2022-03-03 00:00:00 ET · period of report 2022-03-01 · accession 0001077183-22-000038 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-03-03 | 2022-03-01 | NEO | Wallar Gina M | Pres, Pharma Services | A - Grant | $0.00 | +11.7K | 33.4K | +54% | $0 |
| D | 2022-03-03 | 2022-03-01 | NEO | Wallar Gina M | Pres, Pharma Services | A - Grant | $0.00 | +28.5K | 28.5K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-03-01 | A | A | 11,677 | $0.00 | 33,443 | D | — | — | (F1) On March 1, 2022, Ms. Wallar was granted 11,677 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. (F2) This balance includes 104 shares that were acquired at a price of $19.16 per share pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the month ended January 31, 2022. The shares wereacquired in transactions exempt from Section 16b-3. |
| 2 | Derivative | Stock Option (Right to Buy) | 2022-03-01 | A | A | 28,506 | $0.00 | 28,506 | D | $21.41 · — to 2029-03-01 | 28,506 Common Stock | (F9) On March 1, 2022, Ms. Wallar was granted 28,506 stock options. These options vest ratably over the first four anniversary dates of the grant date. |